Syros is a clinical-stage life sciences company dedicated to developing therapies that control gene expression with the aim of providing a profound and durable benefit for patients.
For our lead program, tamibarotene, an oral, selective retinoic acid receptor alpha agonist currently in a pivotal Phase 3 trial (formerly SY-1425), we hold commercial rights in the United States, Europe and several other countries outside of APAC and will be considering a partnership to commercialize in the territories outside the United States.
For SY-2101 (oral arsenic trioxide), we hold worldwide rights and will also be considering partnering commercial rights outside of the United States to allow us to expand our geographic reach.
Additionally, we have worldwide rights for SY-5609, an oral reversible inhibitor of CDK7 with best-in-class selectivity and potency, and will be seeking a partnership for further development.
We also seeking out-licensing opportunities for our additional oncology discovery programs, including SY-12882, our oral CDK12 inhibitor, and programs targeting the inhibition of CDK11 and WRN.
Contact us at email@example.com to learn more about partnership opportunities.